Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ruxolitinib for Severe Fever with Thrombocytopenia Syndrome
ChiCTR2200063759Phase 4Recruiting
- Sponsor
- Qilu Hospital of Shandong University
- Start
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of ruxolitinib in severe fever with thrombocytopenia syndrome (SFTS), sponsored by Qilu Hospital of Shandong University. Primary endpoint: Mortality. Started May 2022; status: recruiting.
02
Drugs
03
Conditions
severe fever with thrombocytopenia syndrome (SFTS)
Beyond the preview
Go deeper on ChiCTR2200063759.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200063759.